PHC-HOLDINGS-CORPORATION
1.4.2019 10:02:10 CEST | Business Wire | Press release
PHC Holdings Corporation (headquarters: Minato-ku Tokyo, Japan, hereafter PHCHD) has today announced that Michael Kloss has taken up the position of President and CEO of PHCHD effective April 1, 2019. Michael succeeds Hidehito Kotani, who has today stepped down as President and CEO.
With more than 20-years of experience in the healthcare industry, Michael Kloss joined PHCHD in 2016 following the acquisition of diabetes care business from Bayer AG and became President and CEO of the newly founded Ascensia Diabetes Care Holdings AG. He has led the diabetes care business throughout the sale from Bayer and has helped to establish Ascensia as a leading diabetes care solutions company.
At an inauguration speech at PHCHD in Tokyo today, Michael Kloss officially stated, “As I take over this role as CEO of PHCHD, we are entering an immensely exciting time for the company. Our ambition is to build a healthcare company with leading global businesses in diabetes care, diagnostics and life sciences alongside a strong healthcare solutions business in Japan. We will achieve this by growing our existing business segments and identifying new ways to expand our products and services. This will enable us to successfully deliver on our mission to contribute to the wellbeing of society by providing solutions for people who wish for better health.”
Michael explained, “The journey for PHCHD started in 2014, when our business carved out from Panasonic group and we set up a Panasonic Healthcare. Since then we have acquired the diabetes care business from Bayer to establish Ascensia Diabetes Care, experienced steady growth across our business segments, and changed our name to PHC Holdings. We are now about to move into the next transformative phase in the development of our company with the proposed addition of the Anatomical Pathology business from Thermo Fisher. Through this potential acquisition, we are adding a new and highly successful business that is showing considerable growth.”
PHC Holdings currently offers value-added products and services through three core businesses: Medical Devices, Life Sciences and Healthcare IT. In January 2019, PHCHD announced the signing of an agreement to acquire the Anatomical Pathology business from Thermo Fisher.
Michael added, “I am thrilled and honored to be taking over this role leading PHCHD and look forward to working with our highly talented employees to successfully grow our business. We have a world-class portfolio of state-of-the-art products and an innovative pipeline of new solutions that can address the unmet needs in healthcare. Our priority is to continue to deliver new value to our customers that will help to build a future of better healthcare for people across the world.”
About PHC Holdings Corporation
Incorporated in 2014, PHC Holdings Corporation is a global healthcare company. Its subsidiaries include PHC Corporation and Ascensia Diabetes Care Holdings AG. Committed to its corporate mission, “We contribute to the wellbeing of society through our diligent efforts by creating new value propositions for all the people who wish for better health,” the company develops, manufactures, sells and services medical equipment and solutions across diabetes care, diagnostics, life sciences and healthcare IT. PHC Holdings Corporation group’s consolidated net sales in FY2017 was 192.6 billion yen with global distribution of products and services for more than 125 countries.
For further information on PHC Holdings Corporation, please visit www.phchd.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190401005284/en/
Contact:
Corporate Communications Group PHC Holdings Corporation Masayo Okada, +81-3-6778-5311
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 15:15:00 CEST | Press release
NVentures, ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures join CapitalG, a16z, Menlo Ventures, and others in backing the high-growth AI infrastructure startup OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leadi
Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 15:00:00 CEST | Press release
Xsolla Adds New Features For Creators, Community Leader Experience, And Distinct Channels For Emerging Markets Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release
First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release
Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom